- Home
- HKIT vs PPBT Comparison
HKIT vs PPBT Comparison
Compare HKIT & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HKIT | PPBT |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.9M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HKIT | PPBT |
|---|---|---|
| Price | $3.48 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 7.6M | 32.0K |
| Earning Date | 04-24-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.41 |
| 52 Week High | $8.80 | $5.18 |
Technical Indicators
Market Signals| Indicator | HKIT | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 60.60 | 30.85 |
| Support Level | $1.69 | $0.58 |
| Resistance Level | $4.21 | $1.41 |
| Average True Range (ATR) | 0.50 | 0.11 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 33.51 | 10.81 |
Price Performance
Historical ComparisonAbout HKIT Hitek Global Inc.
Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of business services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from Hardware and equipment sales, Tax services, and Software sales.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.